Interstitial Lung Disease clinical trials at UC Irvine
2 in progress, 1 open to eligible people
Showing trials for
Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)
open to eligible people ages 18 years and up
Study RIN-PF-305 is designed to evaluate the safety and efficacy of inhaled treprostinil in subjects with progressive pulmonary fibrosis (PPF) over a 52-week period.
Orange, California and other locations
Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis
Sorry, in progress, not accepting new patients
Study RIN-PF-301 is designed to evaluate the superiority of inhaled treprostinil against placebo for the change in absolute forced vital capacity (FVC) from baseline to Week 52.
Orange, California and other locations
Our lead scientists for Interstitial Lung Disease research studies include Bassam Yaghmour, MD.
Last updated: